Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Research Finds Three-Drug Combo With AstraZeneca’s Casodex Kills Prostate Cancer

This article was originally published in PharmAsia News

Executive Summary

Australian researchers report that a combination of three prostate drugs is effective in killing cancer cells with fewer side effects than current drugs. The combination centers AstraZeneca's Casodex (bicalutamide) in low doses to make either of the other two drugs 10 times more effective in their treatment of advanced prostate cancer. The researchers said their laboratory experiments indicate none of the three drugs is as effective in killing prostate cancer cells if used alone. The other drugs used in the experiments were inhibitors 17AAG and Merck's Zolinza (vorinostat). The scientists have begun Phase I clinical trials on the combination. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts